TICKERNERD
Menu
CLBTCLBTTechnology · Software - Infrastructure

CLBT Stock Forecast: Cellebrite DI Ltd. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$11
−0.63% on the day

The 8 Wall Street analysts covering Cellebrite DI Ltd. hold a median 12-month price target of $15 — +35.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 2 Oct 2026 — in the lower half.

Market cap
$2.8B
Ticker Nerd rank
43 / 100
Median analyst target
$15
Analysts covering
8
Revenue$131.1M+15.8% y/y
Operating income$6.9M
Net income$6.4M
Free cash flow$6.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.6%
1M
−4.7%
YTD
−38.6%
1Y
−41.0%
From 52W high
−43.4%
From 52W low
+6.0%
$10
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLBT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cellebrite DI Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Oct 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Growth
69
Accruals
63
Value
60
Volatility
40
Revisions
37
Issuance
36
Size
32
Momentum
18

Quality (91): The business earns solid, repeatable profits on what it owns.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLBT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLBT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20Jan 26Apr 26Jul 26Oct 26CLBTHigh $20Median $15Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $13Median $15High $20

The green dot is the last close — the median target sits +35.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
15 Sept 2026DA DavidsonMaintainsBuy$15
14 Aug 2026DA DavidsonMaintainsBuy—
14 Aug 2026DA DavidsonMaintainsBuy$22 → $15
14 Aug 2026JP MorganMaintainsOverweight$20 → $16
14 Aug 2026JP MorganMaintainsOverweight—
14 Aug 2026Lake StreetMaintainsBuy—
14 Aug 2026Lake StreetMaintainsBuy$21 → $15
14 Aug 2026NeedhamMaintainsBuy$15 → $13
14 Aug 2026NeedhamMaintainsBuy—
6 Aug 2026DA DavidsonMaintainsBuy—
6 Aug 2026DA DavidsonMaintainsBuy$20 → $22
27 May 2026DA DavidsonInitiatesBuy—
27 May 2026DA DavidsonInitiatesBuy$20
15 May 2026NeedhamMaintainsBuy—
12 Feb 2026NeedhamMaintainsBuy—
13 Nov 2025B of A SecuritiesMaintainsBuy—
13 Nov 2025JP MorganMaintainsOverweight—
13 Nov 2025Lake StreetMaintainsBuy—
13 Nov 2025NeedhamMaintainsBuy—
24 Sept 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLBT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CLBT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Cellebrite DI Ltd. returned −41.0% against +16.2% for the S&P 500, dividends included.

CLBT vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26CLBTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLBT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.2%
Analysts raising
3
Analysts cutting
4
Fundamentals

Cellebrite DI Ltd. (CLBT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
49.0×

Cheaper than 15% of US stocks

Price / sales
5.5×

Cheaper than 23% of US stocks

Price / book
5.2×

Cheaper than 19% of US stocks

EV / EBITDA
30.7×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
15.8%

Higher than 64% of US stocks

Earnings growth (YoY)
−67.3%

Higher than 7% of US stocks

Gross margin
80.8%

Higher than 92% of US stocks

Operating margin
5.3%

Higher than 55% of US stocks

Net margin
11.4%

Higher than 72% of US stocks

Returns & dividend
Return on equity
12.4%

Higher than 69% of US stocks

Return on assets
3.9%

Higher than 71% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cellebrite DI Ltd. (CLBT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cellebrite DI Ltd. has a market value of $2.8B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $514.3M. The latest quarter grew 15.8% year on year.

  • Net income over the same four quarters: $58.8M, a 11.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.22.

  • Free cash flow in the twelve months to 30 June 2026: $128.6M.

  • Shares outstanding: 250.8M.

  • Trailing P/E: 49.0×; forward P/E: 17.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cellebrite DI Ltd. employs 1,285 people — $400K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Oct 2026

Data provided by Twelve Data

Peers

CLBT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSoftware - Infrastructure
CompanyMarket capTKN rank
CLBTCellebrite DI Ltd.$2.8B
43
FIVNFive9, Inc.$2.6B
83
APPNAppian Corp.$2.7B
98
TDCTeradata Corp.$2.8B
99
PAGSPagSeguro Digital Ltd.$2.5B
67
INFQInfleqtion, Inc.$2.8B
23
EEFTEuronet Worldwide, Inc.$2.4B
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cellebrite DI Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLBT news & analysis

CLBT INVESTIGATION: Cellebrite Investigated by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses

Newsfile Corp · 2 Oct 2026negative

Block & Leviton is investigating Cellebrite DI for potential securities law violations. The firm has asked investors who have lost money in their Cellebrite investment to contact them to learn about possibly recovering those losses.

Why it matters — CLBT watchers would care because the firm is facing a securities investigation, which could signal legal and regulatory risk for the company.

Cellebrite's 2026 Outlook: Subscription Pivot Weighs on the Stock Today, Helps Lead a Future Rebound

The Motley Fool · 29 Sept 2026negative

Cellebrite's 2026 outlook reflects a subscription-business pivot that is weighing on the stock today but could support a future rebound. The article also notes recent guidance resets and CEO turnover highlight execution risks for the software transition.

Why it matters — CLBT watchers would care because the subscription pivot, guidance resets, and leadership change underscore near-term execution risks even as the company's deep government and law enforcement integration maintains a strong competitive moat.

Kaplan Fox Advises Investors of Cellebrite DI Ltd. (CLBT) to Contact the Firm Regarding a Securities Investigation

Newsfile Corp · 24 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Cellebrite DI Ltd. (NASDAQ: CLBT). The law firm is advising investors to contact them regarding the investigation.

Why it matters — An active securities investigation introduces legal and regulatory uncertainty for Cellebrite that CLBT watchers would want to monitor.

FAQ

Frequently asked questions about CLBT stock

What is the CLBT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Cellebrite DI Ltd. have a median 12-month price target of $15, with estimates ranging from $13 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLBT stock a buy right now?

Of the 8 analysts covering Cellebrite DI Ltd., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cellebrite DI Ltd. 43 out of 100 across roughly 4,600 US stocks as at 2 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLBT?

As at 2 Oct 2026, Cellebrite DI Ltd. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will CLBT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +35.5% from the last close, and Ticker Nerd's factor model ranks Cellebrite DI Ltd. 43 out of 100 as at 2 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLBT stock forecast for 2030?

No analyst covering Cellebrite DI Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLBT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $20 over the next 12 months.

How has CLBT stock performed over the past year?

Cellebrite DI Ltd. returned -41.0% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cellebrite DI Ltd. do?

Cellebrite DI Ltd. is a digital intelligence software company that provides tools for legally sanctioned investigations across public and private sector environments.

What is the latest news on CLBT?

The most recent item we track (Newsfile Corp, 2 Oct 2026): "CLBT INVESTIGATION: Cellebrite Investigated by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses". Block & Leviton is investigating Cellebrite DI for potential securities law violations. The firm has asked investors who have lost money in their Cellebrite investment to contact them to learn about possibly recovering those losses.

Company

About Cellebrite DI Ltd.

Cellebrite DI Ltd. is a digital intelligence software company that provides tools for legally sanctioned investigations across public and private sector environments. Cellebrite DI Ltd. offers a platform used to access, collect, review, extract, decode, decrypt, analyze, share, and manage digital evidence throughout the investigative process. Its products and services support law enforcement, government agencies, and enterprise customers handling complex cases involving mobile devices, cloud data, and other digital sources. The company also provides training, advisory, advanced services, and technical support to help customers use its investigative workflows effectively. Cellebrite DI Ltd. serves a broad range of use cases, including cybercrime, financial crime, organized crime, counterterrorism, border control, and corporate investigations, making it an important provider in the digital forensics and investigative technology market.

CEO Mr. Shiven Ramji · 1,285 employees · Israel · https://www.cellebrite.com